CMS quietly ended a pay-for-performance plan for Novartis' Kymriah—a half-million-dollar cancer treatment; President Donald Trump’s nomination of Judge Brett M. Kavanaugh to the Supreme Court sets up an intense partisan fight over health care; lawmakers in Maine's state House failed to override Republican Governor Paul LePage's veto of a bill that would fund the first year of Medicaid expansion.
CMS quietly killed a pay-for-performance plan for a chimeric antigen receptor (CAR) T-cell therapy—Novartis' Kymriah, which is a half-million-dollar cancer treatment, Politico reported. The deal drew internal HHS scrutiny and is the target of current congressional investigations. CMS refused to comment on the story, but Politico said emails showed that administration lawyers were uncomfortable with how much Novartis was influencing the arrangement, including counseling CMS on the payment criteria for the breakthrough drug.
President Donald Trump’s nomination of Judge Brett M. Kavanaugh to the Supreme Court sets up an intense partisan fight over reproductive health care and possibly the Affordable Care Act (ACA). NPR reported that abortion and the ACA are top of mind for a large number of Senate Democrats in their fight to persuade moderate Republicans and moderates in their own party to oppose Kavanaugh. Senate Majority Leader Mitch McConnell, R-Kentucky, leads the slimmest of majorities and had expressed misgivings about Kavanaugh's path to confirmation, but said he was a “superb choice.”
Lawmakers in Maine's state House failed to override Republican Governor Paul LePage's veto of a bill that would fund the first year of Medicaid expansion, The Hill reported. The 85-58 vote of the $60 million bill fell short of the two-thirds majority needed to pass. Maine voters approved Medicaid expansion last year, but LePage has blocked its implementation. His administration has asked the Maine Supreme Judicial Court to delay the expansion until the state legislature passes a bill funding its share of the costs.